WHO分级对HERBY试验中儿童高级别胶质瘤无预后价值
该研究基于HERBY试验(NCT01390948)的神经病理复核数据,评估WHO 2007分级在儿童新诊断非脑干高级别胶质瘤中的预后价值。实时中央病理复核可行且中位耗时2.4天,163例中20例(12.3%)被排除HGG诊断。最终分析118例,WHO分级与总生存无显著关联,而H3F3A K27M突变、中线位置和高Ki-67指数(≥20%)与不良预后相关。
要点
- WHO 2007 III级与IV级在儿童高级别胶质瘤中无预后差异。
- H3F3A K27M突变与更差的总生存显著相关。
- 中线位置和高Ki-67指数(≥20%)提示预后不良。
核心结论
- WHO III级与IV级分级对儿童高级别胶质瘤的总生存无预后价值。
研究设计与样本
- 基于HERBY前瞻性随机试验(NCT01390948)的神经病理复核数据,纳入新诊断非脑干儿童高级别胶质瘤。
- 随机化前实时中央病理复核采用WHO 2007标准,随后进行盲法共识复核。
- 最终分析人群为118例,评估WHO 2007分级、中线位置及选定生物标志物与总生存的关联。
主要发现
- 实时中央神经病理复核在多中心研究中可行,平均耗时2.4天,163例中20例(12.3%)被排除HGG诊断。
- 不同分级标准及所得WHO分级与总生存在全人群(n=118)及中线/非中线亚组中均无显著关联。
- H3F3A K27M突变与不良预后显著相关。
- 中线位置和高Ki-67指数(≥20%)与不良预后相关(P=0.004和P=0.04)。
- Ki-67指数每增加10%,风险比为1.53(95%CI:1.27-1.83;P<0.0001)。
关键数值与推荐
- WHO 2007分级标准用于实时中央病理复核。
- 将H3F3A K27M突变的中线胶质瘤重新分级为IV级(WHO 2016)后,分级仍无显著预后价值。
- 高Ki-67指数定义为≥20%。
临床怎么用
- 儿童高级别胶质瘤的预后评估应关注H3F3A K27M突变、中线位置和Ki-67指数,而非仅依赖WHO分级。
- 多中心试验中实时中央病理复核可行,有助于确保诊断准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The World Health Organization (WHO) adult glioma grading system is questionable in pediatric high-grade gliomas (pHGGs), which are biologically distinct from adult HGGs. We took advantage of the neuropathological review data obtained during one of the largest prospective randomized pHGG trials, namely HERBY (NCT01390948), to address this issue in children with newly diagnosed non-brainstem HGG. METHODS: HGG diagnosis was confirmed by pre-randomization, real-time central pathology review using WHO 2007 criteria, followed by a consensus review blinded to clinical factors and outcomes. We evaluated association between WHO 2007 grade and other clinical/radiological/biological characteristics and the prognostic value of WHO 2007 grade, midline location, and selected biomarkers (Ki-67 index/Olig2/CD34/EGFR/p53/H3F3A K27M mutation) on overall survival. RESULTS: Real-time central neuropathological review was feasible in a multicenter study, with a mean time of 2.4 days, and led to the rejection of HGG diagnosis in 20 of 163 cases (12.3%). The different grading criteria and resulting WHO grade were not significantly associated with overall survival in the entire population (n = 118) or in midline and non-midline subgroups. H3F3A K27M mutation was significantly associated with poor outcome. No significant prognostic value was observed for grade, even after regrading H3F3A K27M-mutated midline glioma as grade IV (WHO 2016). Midline location and a high Ki-67 index (≥20%) were associated with poor outcome (P = 0.004 and P = 0.04, respectively). A 10% increase in Ki-67 index was associated with a hazard ratio of 1.53 (95% CI: 1.27-1.83; P < 0.0001). CONCLUSION: Our findings suggest that WHO grade III versus IV has no prognostic value in pediatric HGG.
引用
- Varlet P, Le Teuff G, Le Deley MC, et al. WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial. Neuro Oncol. 2020. PMID: 31419298. doi:10.1093/neuonc/noz142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。